Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

>SHANGHAI, China, March 26, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line […]

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC

Junshi Biosciences Announces Ongericimab’s NDA Approval in China

>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)